Form 4: Pulse Biosciences Director Receives Stock Option Grant

Director Mahkam Zanganeh was granted stock options for 44,504 shares of Pulse Biosciences common stock.

Summary

• Director Mahkam Zanganeh received two grants of stock options totaling 44,504 shares.
• The options have an exercise price of $26.89 per share.
• The grants expire on June 11, 2036.
• The first grant of 30,000 shares vests in equal monthly installments over one year starting July 11, 2026.
• The second grant of 14,504 shares vests in equal quarterly installments over one year starting September 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market price volatility of Pulse Biosciences common stock could impact the value of these options.

Future Outlook

The options vest over a one-year period, indicating a short-term retention and incentive structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure alignment between board members and shareholders, particularly in the biotechnology sector where long-term development cycles are common.

Comparison to Industry Standards

• The use of monthly and quarterly vesting schedules is consistent with standard executive and director compensation packages in the life sciences industry.
• The 10-year expiration term is a standard market practice for non-qualified stock options.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first monthly installment on July 11, 2026.
• Vesting of the first quarterly installment on September 5, 2026.

Key Dates

Keywords

Pulse Biosciences, PLSE, Form 4, Director Compensation, Stock Options, Insider Trading